A study on Shwadanshtradi Taila as Basti in Mutraghata (Benign Prostatic Hyperplasia)

A Clinical, Biochemical and Sonological study on Shwadanshtradi Taila as Uttara Basti in Mutraghata with special reference to Benign Prostatic Hyperplasia - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075930

Enrollment

Registered

2024-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N400- Benign prostatic hyperplasia without lower urinary tract symptoms Health Condition 2: O- Medical and Surgical

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed case of Bladder Outflow Obstruction (BOO) with Benign Prostate Enlargement (BPE) Age 50 to 75 years. Patients will be selected irrespective of caste and religion

Exclusion criteria

Exclusion criteria: Neurogenic bladder Urethral Stricture Adenocarcinoma of Prostate Uncontrolled Diabetes Mellitus Subjects with CRF. Subjects with Venereal Diseases

Design outcomes

Primary

Measure	Time frame
Laboratory Investigations like Complete Blood Count, Erythrocyte Sedimentation Rate, FBS and PPBS, Renal FunctionTest, Liver function Test, HIV, HBsAg, Anti HCV. Urine Analysis: Routine & Microscopic examination, Culture & Sensitivity. Radiological Investigation: USG of prostate,Trans Rectal Ultrasonography. Biochemical Evaluation: Prostate Specific Antigen (PSA). Urodynamic Study: Uroflowmetry will be assessedTimepoint: 15 days	—

Measure

Time frame

Laboratory Investigations like Complete Blood Count, Erythrocyte Sedimentation Rate, FBS and PPBS, Renal FunctionTest, Liver function Test, HIV, HBsAg, Anti HCV. Urine Analysis: Routine & Microscopic examination, Culture & Sensitivity. Radiological Investigation: USG of prostate,Trans Rectal Ultrasonography. Biochemical Evaluation: Prostate Specific Antigen (PSA). Urodynamic Study: Uroflowmetry will be assessedTimepoint: 15 days

—

Secondary

Measure	Time frame
Clinical Evaluation: IPSS (International Prostate Symptom Score): Incomplete emptying Frequency, Intermittency, Urgency, Weak Stream, Straining, Nocturia will be assessed.Timepoint: 15 days	—

Countries

India

Contacts

Public ContactDr Suraj Kumar Sahu

Institute of Medical Sciences, Banaras Hindu University

drlsingh@bhu.ac.in9415687065

Outcome results